Tumor necrosis factor alpha-an underestimated risk predictor in patients undergoing transcatheter aortic valve replacement (TAVR)?
Moritz MirnaMario HolnthonerAlbert TopfPeter JirakDzeneta FejzicVera PaarJörg KellermairHermann BlessbergerChristian ReiterJürgen KammlerLukas J MotlochChristian JungDaniel KretzschmarMarcus FranzBrunilda AlushiAlexander LautenUta C HoppeClemens SteinwenderMichael LichtenauerPublished in: Journal of clinical laboratory analysis (2021)
Plasma levels of TNF-α after 24 h and 5 days were independently associated with 12-month mortality in patients undergoing TAVR. Thus, TNF-α could represent a novel biomarker for enhanced risk stratification in these patients.
Keyphrases
- transcatheter aortic valve replacement
- patients undergoing
- aortic stenosis
- aortic valve
- ejection fraction
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- cardiovascular events
- peritoneal dialysis
- left ventricular
- heart failure
- cardiovascular disease
- patient reported outcomes
- patient reported